Skip to content

Lung Cancer Health Center

Font Size

Stage IV NSCLC Treatment

    Forty percent of patients with newly diagnosed non-small cell lung cancer (NSCLC) have stage IV disease. Treatment goals are to prolong survival and control disease-related symptoms. Treatment options include cytotoxic chemotherapy and targeted agents. Factors influencing treatment selection include comorbidity, performance status (PS), histology, and molecular genetic features of the cancer. Radiation therapy and surgery are generally used in selective cases for symptom palliation.

    Standard Treatment Options for Stage IV NSCLC

    Recommended Related to Lung Cancer

    Stage Information for NSCLC

    Background In NSCLC, the determination of stage is important in terms of therapeutic and prognostic implications. Careful initial diagnostic evaluation to define the location and to determine the extent of primary and metastatic tumor involvement is critical for the appropriate care of patients. In general, symptoms, physical signs, laboratory findings, or perceived risk of distant metastasis lead to an evaluation for distant metastatic disease. Additional tests such as bone scans and computed...

    Read the Stage Information for NSCLC article > >

    Standard treatment options for stage IV NSCLC include the following:

    1. Cytotoxic combination chemotherapy (first line) with platinum (cisplatin or carboplatin) and paclitaxel, gemcitabine, docetaxel, vinorelbine, irinotecan, and pemetrexed.
      1. Factors influencing treatment.
        • Histology.
        • Age versus comorbidity.
        • PS.
    2. Combination chemotherapy with bevacizumab or cetuximab.
    3. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (first line) (for patients with EGFR mutations).
    4. EML4-ALK inhibitors in patients with EML-ALK translocations.
    5. Maintenance therapy following first-line chemotherapy (for patients with stable or responding disease following four cycles of non–pemetrexed-platinum combination chemotherapy).
    6. Endobronchial laser therapy and/or brachytherapy (for obstructing lesions).[1]
    7. External-beam radiation therapy (EBRT) (primarily for palliation of local symptomatic tumor growth).[2,3,4]

    Randomized controlled trials of patients with stage IV disease and good PS have shown that cisplatin-based chemotherapy improves survival and palliates disease-related symptoms.[5][Level of evidence: 1iiA] Patients with nonsquamous cell histology, good PS, no history of hemoptysis or other bleeding, or recent history of cardiovascular events may benefit from the addition of bevacizumab to paclitaxel and carboplatin. Patients with tumors harboring mutations in EGFR, particularly those from East Asia, never smokers, and those with adenocarcinoma may benefit from EGFR tyrosine kinase inhibitors as an alternative to first- or second-line chemotherapy. Second-line chemotherapy with docetaxel, pemetrexed, or erlotinib also improves survival in patients with good PS.[5][Level of evidence: 1iiA] The role of chemotherapy in patients with poor PS was less certain.

    Cytotoxic combination chemotherapy (first line)

    The type and number of chemotherapy drugs to be used for the treatment of patients with advanced NSCLC has been extensively evaluated in randomized controlled trials and meta-analyses.

    Several randomized trials have evaluated various drugs combined with either cisplatin or carboplatinum in previously untreated patients with advanced NSCLC. Based on meta-analyses of the trials, the following conclusions can be drawn:

    • Certain three-drug combinations that add so-called targeted agents may result in superior survival.
    • EGFR inhibitors may benefit selected patients with EGFR mutations.
    • Maintenance chemotherapy following four cycles of platinum combination chemotherapy may improve progression-free survival (PFS).
    • Platinum combinations with vinorelbine, paclitaxel, docetaxel, gemcitabine, irinotecan, and pemetrexed yield similar improvements in survival. Types and frequencies of toxic effects differ, and these may determine the preferred regimen for an individual patient. Patients with adenocarcinoma may benefit from pemetrexed.
    • Cisplatin and carboplatinum yield similar improvements in outcome with different toxic effects. Some, but not all, trials and meta-analyses of trials suggest that outcomes with cisplatin may be superior, although with a higher risk of certain toxicities such as nausea and vomiting.
    • Nonplatinum combinations offer no advantage to platinum-based chemotherapy, and some studies demonstrate inferiority.
    • Three-drug combinations of the commonly used chemotherapy drugs do not result in superior survival and are more toxic than two-drug combinations.
      1|2|3|4|5|6|7|8|9|10

      Today on WebMD

      Broken cigarette
      Do you know the myths from the facts?
      man with a doctor
      Our health check will steer you in the right direction.
       
      sauteed cherry tomatoes
      Fight cancer one plate at a time.
      Lung cancer xray
      See it in pictures, plus read the facts.
       
      15 Cancer Symptoms Men Ignore
      FEATURE
      Lung Cancer Risks Myths and Facts
      SLIDESHOW
       
      cancer fighting foods
      SLIDESHOW
      Improving Lung Cancer Survival Targeted Therapy
      VIDEO
       
      Lung Cancer Surprising Differences Between Sexes
      VIDEO
      Pets Improve Your Health
      SLIDESHOW
       
      Vitamin D
      SLIDESHOW
      Lung Cancer Surgery Options
      VIDEO
       

      WebMD Special Sections